Natalie Callander, MD

Considerations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.

Current combination approaches, including BCMA-targeting agents like belantamab mafodotin, being explored to address treatment gaps in relapsed/refractory multiple myeloma.

An overview of novel bispecific therapies under development in relapsed/refractory multiple myeloma.

Implications for treating patients with relapsed/refractory multiple myeloma with CAR T cells vs antibody-drug conjugates.

Recommendations for managing ocular toxicities associated with belantamab mafodotin when used as treatment for relapsed/refractory multiple myeloma.

Dr. Natalie Callander reviews data from the DREAMM-5 study presented at ASH 2021, which assessed the safety and efficacy of belantamab mafodotin plus feladilimab in patients with relapsed/refractory multiple myeloma with disease resistance to at least 3 prior lines of therapy.

What to know in terms of dosing belantamab mafodotin treatment in patients with relapsed/refractory multiple myeloma.

Variables that impact treatment decisions for relapsed/refractory multiple myeloma.

Natalie Callander, MD, presents the profile of a female patient with relapsed/refractory multiple myeloma who receives belantamab mafodotin and develops keratopathy.

Karen L. Klugo, MD, describes what’s unique in terms of patient response to belantamab mafodotin as treatment for relapsed/refractory multiple myeloma and risk of ocular disease.

The rationale for treating relapsed/refractory multiple myeloma with belantamab mafodotin, and studies investigating the drug’s potential in earlier treatment settings.

Sagar Lonial, MD, FACP, highlights a novel treatment option available for a 57-year-old man whose disease progresses after 3 prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.